RT Journal Article SR Electronic T1 Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.11.02.20223891 DO 10.1101/2020.11.02.20223891 A1 Genay Pilarowski A1 Paul Lebel A1 Sara Sunshine A1 Jamin Liu A1 Emily Crawford A1 Carina Marquez A1 Luis Rubio A1 Gabriel Chamie A1 Jackie Martinez A1 James Peng A1 Douglas Black A1 Wesley Wu A1 John Pak A1 Matthew T. Laurie A1 Diane Jones A1 Steve Miller A1 Jon Jacobo A1 Susana Rojas A1 Susy Rojas A1 Robert Nakamura A1 Valerie Tulier-Laiwa A1 Maya Petersen A1 Diane V. Havlir A1 The CLIAHUB Consortium A1 Joseph DeRisi YR 2020 UL http://medrxiv.org/content/early/2020/11/04/2020.11.02.20223891.abstract AB We evaluated the performance of the Abbott BinaxNOW™ Covid-19 rapid antigen test to detect virus among persons, regardless of symptoms, at a public plaza site of ongoing community transmission. Titration with cultured clinical SARS-CoV-2 yielded a human observable threshold between 1.6×104-4.3×104 viral RNA copies (cycle threshold (Ct) of 30.3-28.8 in this assay). Among 878 subjects tested, 3% (26/878) were positive by RT-PCR, of which 15/26 had a Ct<30, indicating high viral load. 40% (6/15) of Ct<30 were asymptomatic. Using this Ct<30 threshold for Binax-CoV2 evaluation, the sensitivity of the Binax-CoV2 was 93.3% (14/15), 95% CI: 68.1-99.8%, and the specificity was 99.9% (862/863), 95% CI: 99.4-99.9%.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by UCSF, the Chan Zuckerberg Biohub, the Chan Zuckerberg Initiative, the San Francisco Latino Task Force, and a private donor. BinaxNOWTM COVID-19 Ag cards were generously donated by Abbott for the study and LR was funded by T32 AI060530.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UCSF Committee on Human Research determined that the study met criteria for public health surveillance. All participants provided informed consent for dual testing.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is included in the figures of the manuscript. Supplemental material (Binax-CoV2 reader training guide) is included in the link. https://unitedinhealth.org/binax-training